Cargando…

Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer

Detalles Bibliográficos
Autores principales: Kwon, Jennifer, MEAGHER, ALISON
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093347/
https://www.ncbi.nlm.nih.gov/pubmed/25031955
_version_ 1782325708746391552
author Kwon, Jennifer
MEAGHER, ALISON
author_facet Kwon, Jennifer
MEAGHER, ALISON
author_sort Kwon, Jennifer
collection PubMed
description
format Online
Article
Text
id pubmed-4093347
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-40933472014-07-16 Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer Kwon, Jennifer MEAGHER, ALISON J Adv Pract Oncol Review Article Harborside Press 2012 2012-07-01 /pmc/articles/PMC4093347/ /pubmed/25031955 Text en Copyright © 2012, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Review Article
Kwon, Jennifer
MEAGHER, ALISON
Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
title Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
title_full Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
title_fullStr Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
title_full_unstemmed Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
title_short Crizotinib: A Breakthrough for Targeted Therapies in Lung Cancer
title_sort crizotinib: a breakthrough for targeted therapies in lung cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093347/
https://www.ncbi.nlm.nih.gov/pubmed/25031955
work_keys_str_mv AT kwonjennifer crizotinibabreakthroughfortargetedtherapiesinlungcancer
AT meagheralison crizotinibabreakthroughfortargetedtherapiesinlungcancer